Jan Hendrik Beumer was appointed Associate Professor in the Department of Pharmaceutical Sciences at the University of Pittsburgh, School of Pharmacy in July 2014.
Dr. Beumer received a Doctorate of Pharmacy in 2001 from the University of Utrecht, Faculty of Pharmaceutical Sciences, Utrecht, The Netherlands. Subsequently, he worked as a research pharmacist under the supervision of professor Jos H Beijnen, professor Jan HM Schellens and Dr. Olaf van Tellingen at the Department of Pharmacy and Pharmacology, Slotervaart Hospital / The Netherlands Cancer Institute, Amsterdam, The Netherlands, which, in 2004, resulted in a PhD from the University of Utrecht, Utrecht, The Netherlands. Subsequently, Dr. Beumer joined Professor Merrill Egorin's group at the University of Pittsburgh Cancer Institute through the School of Medicine, departmeant of heamatology/Oncology in 2005 as a post-doctoral associate.
Dr Beumer has established an active program of healthy volunteer drug-drug interaction studies, designed several phase I studies of novel combinations of anticancer agents, and has extensively researched pyrimidine anticancer drug pharmacology. He is an expert in preclinical and clinical metabolic studies, with a focus on mass balance studies. He also serves as Director of the University of Pittsburgh Cancer Institute Clinical Pharmacology Analytical Facility, which also functions as the core facility of the Gynecologic Oncology Group (GOG) and the Cancer and Leukemia Group B (CALGB). Through these roles, he is intimately involved in the design, execution, supervision and data analysis of numerous pharmacokinetic and metabolic studies of anti-cancer drugs covering the entire spectrum from preclinical to clinical phase II studies. For several years, he has been a co-investigator and is currently co-PI on an NCI N01 Animal Pharmacology Contract and I am co-PI of the UPCI NCI/CTEP U01 Phase I Grant.
Dr Beumer has published over 70 manuscripts in various peer-reviewed journals and has been been invited to present his work at national and international meetings including the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), PittCon, and the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Dr Beumer's goal is to study the translational pharmacology of anticancer drugs and to play a critical role in facilitating and mediating the preclinical and clinical drug development process. The translational science that is conducted in his laboratory provides significant contributions to the cancer research community at the University of Pittsburgh Cancer Institute, the Department of Pharmacutical Sciences, as well as at the NCI, various cooperative groups, other academic centers, and the pharmaceutical industry with the eventual goal of enhancing the quality of care of our cancer patients.